Global News

OrbiMed launches $307M Israel venture capital fund

Tuesday, May 24, 2016

OrbiMed, an investment firm focused on the healthcare sector, announced the closing of its second Israel-focused venture capital fund, OrbiMed Israel Partners II, LP, with approximately $307 million in capital commitments. Investors in the fund include several of the world’s largest healthcare companies, in addition to dozens of institutional investors and family offices.

[Read More]

Merrimack, Baxalta initiate phase I study of MM-151 for colorectal cancer

Tuesday, May 24, 2016

Merrimack Pharmaceuticals and Baxalta are initiating a phase I clinical study of Merrimack’s oligoclonal EGFR (epidermal growth factor receptor) inhibitor, MM-151, in combination with ONIVYDE (irinotecan liposome injection) plus fluorouracil (5-FU) and leucovorin in patients with RAS wild-type metastatic colorectal cancer. Data from a prior phase I study of MM-151 supports further clinical evaluation of the investigational therapy in patients with metastatic colorectal cancer.

[Read More]

Acorda to discontinues PLUMIAZ for epilepsy

Tuesday, May 24, 2016

Acorda Therapeutics will discontinue development of PLUMIAZ (diazepam) Nasal Spray, an investigational therapy being studied for the treatment of seizure clusters in people with epilepsy. Data from the ongoing clinical trials do not demonstrate its bioequivalence to Diastat rectal gel, needed to re-file the New Drug Application (NDA) under section 505(b)(2). Specifically, the data demonstrated unexpectedly lower nasal mucosa absorption of diazepam in persons with epilepsy compared to studies in healthy volunteers.

[Read More]

Sunovion releases long-term data of biopolar depression treatment Latuda

Monday, May 23, 2016

Sunovion Pharmaceuticals has published results in the journal Depression and Anxiety from a six-month, open-label extension study that evaluated the long-term safety, tolerability and effectiveness of Latuda (lurasidone HCI) when used either as monotherapy or as adjunctive therapy in combination with lithium or valproate in adults with major depressive episodes associated with bipolar I disorder (bipolar depression).

[Read More]

Sunovion releases positive data for COPD inhalation solution Brovana

Monday, May 23, 2016

Sunovion Pharmaceuticals has announced the results of a post-hoc analysis of a long-term safety study evaluating Brovana (arformoterol tartrate) Inhalation Solution in people with moderate-to-severe chronic obstructive pulmonary disease (COPD). Results from this analysis reinforce the use of Brovana in COPD, as measured by COPD exacerbation-related hospitalizations compared to those treated with placebo.

[Read More]

Intrexon appoints Geno Germano president

Monday, May 23, 2016

Intrexon, a provider of synthetic biology, has appointed Geno Germano to the new role of president of Intrexon effective June 1, reporting to Chairman and Chief Executive Officer Randal J. Kirk. As president, Germano will help lead Intrexon’s management team and commercialization efforts utilizing the company’s technology platform for biologically-based solutions across a broad range of industries. Each of Intrexon’s five sectors and the office of the chief operating officer will report to Germano. 

[Read More]